Clinical Trials Browser

Recruiting × Lymphoma, Non-Hodgkin × Immunotherapy, Adoptive × Clear all

NCT07052305 2026-02-12

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Phase 1 Recruiting

24 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT04545762 2026-01-14

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1 Recruiting

36 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06104592 2026-01-08

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Phase 2 Recruiting

27 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT05260957 2025-12-31

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Phase 2 Recruiting

22 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT02917083 2025-07-25

RELY-30

Phase 1 Recruiting

60 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT04532203 2020-10-26

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Phase EARLY_PHASE1 Recruiting

72 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma